Y10S623/915

Methods for Vascular Construction and Products Therefrom
20200360563 · 2020-11-19 ·

The present invention is directed to vascular tissue constructs or vessels and methods for producing vascular tissue constructs or vessels (ie., fabricated blood vessels), including veins, arteries, capillaries and other vascular structures from a biomaterial foundation or scaffold and epicardial progenitor cells (EPCs) which are seeded onto the biomaterial, exposed to a differentiation medium and differentiated into endothelial, cells, smooth muscle cells and pericytes which self-assemble into vascular tissue associated with N the biomaterial foundation or scaffold.

Multiple-layer immune barrier for donor cells

A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure, the second alginate structure having a mannuronic acid concentration of between 52% and 60%. A selectively-permeable membrane is coupled at least in part to the second alginate structure. Other embodiments are also described.

MULTIPLE-LAYER IMMUNE BARRIER FOR DONOR CELLS

A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure, the second alginate structure having a mannuronic acid concentration of between 52% and 60%. A selectively-permeable membrane is coupled at least in part to the second alginate structure. Other embodiments are also described.

Multiple-layer immune barrier for donor cells

A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure, the second alginate structure having a mannuronic acid concentration of between 52% and 60%. A selectively-permeable membrane is coupled at least in part to the second alginate structure. Other embodiments are also described.